Fowler B, Schutgens R B, Rosenblatt D S, Smit G P, Lindemans J
Basel University Children's Hospital, Switzerland.
J Inherit Metab Dis. 1997 Nov;20(6):731-41. doi: 10.1023/a:1005372730310.
This first detailed report of a female patient with functional methionine synthase deficiency due to the cblE defect describes treatment with several vitamins and cofactors and clinical progress for 17 years. Before treatment, major findings were microcephaly, psychomotor retardation, episodic reduced consciousness, megaloblastic anaemia, increased plasma free homocystine (> 20 mumol/L), low plasma methionine (< 10 mumol/L) and increased excretion of formiminoglutamate. On high-dose folic acid, biochemical abnormalities such as formiminoglutamate excretion and homocystinuria nearly normalized, but clinical and haematological abnormalities remained. On replacement of folate with methylcobalamin, alertness, motor function, speech and the electroencephalogram improved, biochemical features were similar, but the mean corpuscular volume increased. The best control was observed on a combination of folate and methylcobalamin. At 17 years of age she remains severely mentally retarded. In cultured fibroblasts methionine synthesis was reduced (0.03 nmol/mg/per 16 h, controls 2.4-6.9); methionine synthase activity was normal under high reducing conditions but decreased on limiting the reducing agent, dithiothreitol, to 5 mmol/L (18% of total, controls 51-81%); formation of methylcobalamin was low (4.5% of total cobalamins, control 57.5%) and complementation studies indicated the cblE defect. Methionine formation showed only minor increases in cells grown in folate- or cobalamin-supplemented medium. Serine synthesis, which was low in normal medium, increased with cobalamin supplementation. These studies suggest further heterogeneity within cblE mutants, show the difficulty of establishing the enzyme defect in vitro, and indicate a role for folate in addition to cobalamin in treatment.
这份关于一名因cblE缺陷导致功能性蛋氨酸合酶缺乏的女性患者的首份详细报告,描述了用多种维生素和辅因子进行的治疗以及17年的临床进展。治疗前,主要表现为小头畸形、精神运动发育迟缓、发作性意识减退、巨幼细胞贫血、血浆游离同型半胱氨酸升高(>20μmol/L)、血浆蛋氨酸降低(<10μmol/L)以及亚胺甲基谷氨酸排泄增加。服用高剂量叶酸后,亚胺甲基谷氨酸排泄和高同型半胱氨酸尿症等生化异常几乎恢复正常,但临床和血液学异常依然存在。用甲钴胺替代叶酸后,警觉性、运动功能、言语及脑电图有所改善,生化特征相似,但平均红细胞体积增加。叶酸和甲钴胺联合使用时控制效果最佳。17岁时她仍严重智力发育迟缓。在培养的成纤维细胞中,蛋氨酸合成减少(0.03nmol/mg/每16小时,对照组为2.4 - 6.9);在高还原条件下蛋氨酸合酶活性正常,但当将还原剂二硫苏糖醇限制在5mmol/L时活性降低(占总量的18% ,对照组为51 - 81%);甲钴胺的形成较低(占总钴胺素的4.5% ,对照组为57.5%),互补研究表明存在cblE缺陷。在补充叶酸或钴胺素的培养基中生长的细胞中,蛋氨酸形成仅略有增加。在正常培养基中较低的丝氨酸合成,随着钴胺素的补充而增加。这些研究表明cblE突变体存在进一步的异质性,显示了在体外确定酶缺陷的困难,并表明在治疗中除钴胺素外叶酸也发挥作用。